Why Rimonabant Acomplia?
Rimonabant has been developed from the knowledge that cannabis smokers often experience extreme hunger pangs, which cannabis smokers refer to as ‘the munchies’.
Specifications - Acomplia (Rimonabant) - Investigational Agent for the Management of Obesity
| Key Data | |
|---|---|
| Drug (brand/generic) | Acomplia / rimonabant |
| Company/licensee | Sanofi-Aventis |
| Therapy class | Cannabinoid receptor antagonist |
| Product description | Selective inhibitor of the CB1 endocannabinoid receptor |
| Current indication | Treatment of obesity in combination with dietary control |
| Market sector | Nutrition |
| Development status | Approved in Europe, pre-registration in the US |
No Comments
No comments yet.
Sorry, the comment form is closed at this time.